ADVENTRX first quarter net loss increases to $4.2M ADVENTRX Pharmaceuticals, Inc. today reported monetary results for the first quarter ended March 31, 2012 dapoxetine 90 mg . In the first quarter, we focused our resources on ANX-188, including manufacturing activities linked to generating scientific trial materials for our planned phase 3 study in sufferers with sickle cell disease, mentioned Brian M. Culley, Chief Executive Officer of ADVENTRX. First Quarter 2012 Operating Outcomes ADVENTRX’s net loss relevant to common share for the first one fourth of 2012 was $4.2 million, or $0.09 per share , in comparison to a net reduction relevant to common stock of $3.0 million, or $0.13 per share , for the same period in 2011.2 million, an increase of $1.6 million, or 262 percent, compared to $0.6 million for the same period in 2011.
Experts say these medications can boost heart rate and blood pressure. ‘The most common cardiac effects are benign – – very small, insignificant increases in heart rate or blood pressure clinically,’ stated Dr. Andrew Adesman, chief of developmental and behavioral pediatrics at Cohen Children’s Medical Center of NY in New Hyde Recreation area. Alarms sounded due to reports of unexpected deaths, heart stroke and attack linked to ADHD drugs, which has led some physicians to assess heart wellness before starting teenagers on the drugs.